Liver Function Assessment Using Technetium 99m-Galactosyl Single-Photon Emission Computed Tomography/CT Fusion Imaging: A Prospective Trial - 23/11/17
, Yasuo Shima, MD a, Sojiro Morita, MD b, Yasuhiro Shimada, MD c, Tatsuaki Sumiyoshi, MD a, Kenta Sui, MD a, Jun Iwata, MD d, Tatsuo Iiyama, MD eAbstract |
Background |
The prediction of postoperative liver function remains a largely subjective practice based on CT volumetric analysis. However, future liver volume after a hepatectomy is not the only factor that contributes to postoperative liver function and outcomes.
Study Design |
In this prospective trial, 185 consecutive patients who underwent liver operations between 2014 and 2015 were studied. Volumetric and functional rates of remnant liver were measured using technetium 99m-galactosyl human serum albumin single-photon emission computed tomography/CT fusion imaging to evaluate post-hepatectomy remnant liver function. Remnant indocyanine green clearance rate using galactosyl (KGSA) (KGSA × functional rate) was used to predict future remnant liver function. Hepatectomy was considered safe for patients with remnant KGSA values ≥0.05, and the primary end point was to determine the accuracy and reliability of this criteria. The prediction of the 90-day major complication and mortality rates was assessed.
Results |
Median hospital stay was 9 days and median ICU stay was 1 day, with only 1 in-hospital death (90-day mortality rate 0.5%). Overall morbidity rate evaluated according to the Clavien-Dindo classification was 9%. For post-hepatectomy liver failure definitions, the International Study Group of Liver Surgery definition was fulfilled in 14 patients (8%), with the majority being grade B (50%), compared with 2 patients (1%) fulfilling the “50-50” criteria, and 0 patients (0%) fulfilling the PeakBili >7 criteria.
Conclusions |
Results of this study showed that remnant KGSA provided information that allowed us to predict remnant liver function. This information will be important for surgeons when deciding on a treatment plan for patients with liver diseases. (ClinicalTrials.gov ID: NCT02013895).
Le texte complet de cet article est disponible en PDF.Abbreviations and Acronyms : ICG R15, ISGLS, rem, KGSA, KICG, LHL15, PHLF, PT-INR, SPECT, 99mTc-GSA
Plan
| Disclosure Information: Nothing to disclose. |
|
| Support: This study was supported by grants from the Kochi Organization for Medical Reformation and Renewal. |
Vol 225 - N° 6
P. 789-797 - décembre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
